Business
Pharvaris Announces Positive Topline Data from RAPIDe-3 Pivotal Study Confirming Potential of Deucrictibant for On-Demand Treatment of HAE Attacks
Primary endpoint met; median time to onset of symptom relief achieved in 1.28 hours, significantly faster versus placebo
About this update from Pharvaris N.v.
[{"type":"text","content":"Primary endpoint met; median time to onset of symptom relief achieved in 1.28 hours, significantly faster versus placebo (p","length":160,"tagName":"div"}]